Medication-Assisted Treatment, or MAT, combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders, primarily opioid and alcohol use disorders. MAT is not a replacement for therapy or recovery work. It is a clinical tool that stabilizes neurochemistry, reduces withdrawal severity, and decreases cravings so that a person can fully engage in the psychological and social dimensions of recovery.

How MAT Works

MAT works by targeting the same receptor systems that drugs of abuse activate, but in a controlled, therapeutic way. For opioid use disorder, the 3 FDA-approved medications are methadone, buprenorphine, and naltrexone. Methadone is a full opioid agonist dispensed through licensed opioid treatment programs; it reduces withdrawal and cravings through continuous receptor activation at non-intoxicating doses. Buprenorphine is a partial opioid agonist that activates opioid receptors partially and has a ceiling effect that limits misuse potential. Naltrexone is an opioid antagonist that blocks the euphoric effects of opioids entirely, making relapse neurologically unrewarding.

For alcohol use disorder, 3 FDA-approved medications serve different functions. Naltrexone reduces alcohol cravings and the rewarding effects of drinking. Acamprosate reduces the anxiety and dysphoria associated with early abstinence. Disulfiram produces an unpleasant reaction when alcohol is consumed, serving as a deterrent. These medications address distinct aspects of the neurobiological experience of alcohol dependence.

‍

‍

The Evidence for MAT

MAT is among the most thoroughly evidence-based interventions in addiction medicine. The Substance Abuse and Mental Health Services Administration reports that MAT for opioid use disorder reduces opioid use, decreases illicit drug use, reduces criminal activity, improves social functioning, and decreases the risk of overdose death. A meta-analysis published in JAMA Psychiatry found that buprenorphine treatment reduced the risk of all-cause mortality by 50 percent compared to no treatment.

Despite this evidence base, MAT remains stigmatized in some recovery communities. Some 12-step groups discourage MAT on the grounds that it represents continued drug dependence. This stigma is not supported by clinical evidence and can be harmful: it causes people to discontinue effective treatment in order to conform to a particular recovery ideology. The clinical consensus among addiction medicine specialists is that MAT is a medical treatment, not a failure of sobriety.

‍

‍

Who Is MAT Appropriate For?

MAT is most appropriate for individuals with moderate to severe opioid or alcohol use disorder, those who have experienced previous relapses despite non-medicated treatment, people with high physical dependence whose withdrawal requires medical management, and individuals with co-occurring mental health conditions that may be worsened by the stress of unaided withdrawal. MAT is also the standard of care for pregnant women with opioid use disorder because untreated opioid withdrawal poses serious risks to fetal health.

Not everyone in addiction treatment requires MAT. For people navigating opioid addiction, the decision to use medication depends on the severity of physical dependence, prior treatment history, and whether previous attempts at abstinence without medication were derailed by withdrawal or craving intensity that proved unmanageable.

Addressing Common Concerns About MAT

The most common concerns about MAT center on 3 questions: Is it just trading one drug for another? How long must a person stay on medication? Will insurance cover it? On the first question: medically, no. MAT medications do not produce the euphoria or behavioral impairment associated with addiction. They stabilize brain chemistry in the same way that antidepressants stabilize mood disorders. On the second: treatment duration varies by individual; some people use MAT for a defined period during early recovery, and others benefit from long-term maintenance. Both approaches are clinically legitimate. On insurance: most plans, including Medicaid, cover FDA-approved MAT medications.

Combining MAT with Behavioral Therapy for the Best Outcomes

The evidence consistently shows that MAT is most effective when combined with counseling and behavioral therapy. Medication alone does not address the psychological, social, and relational dimensions of addiction. A person on buprenorphine who does not engage in therapy is more likely to relapse than one who combines medication with active therapeutic work.

Choosing the right therapeutic approach matters. CBT and DBT each offer distinct benefits for addiction recovery, and understanding the differences helps clients and families make informed decisions about which modality best fits the individual's presentation, particularly when co-occurring anxiety, PTSD, or emotional dysregulation are part of the picture.

For clients who struggle with emotional instability in early recovery, developing strong

DBT emotion regulation skills

provides a practical complement to MAT: medication reduces the physiological pull of craving and withdrawal, while DBT skills address the emotional dysregulation that can trigger relapse even when cravings themselves are well managed.

‍

‍